Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Armala pazopanib: Phase II data

In a U.S. Phase II trial in 37 patients, 800 mg/day

Read the full 119 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE